Chrysotoxine
Based on 1 publication(s) in Google Scholar
Chrysotoxine is a dual inhibitor of Src/Akt. Chrysotoxine suppresses cancer stem cells (CSCs) phenotypes by down-regulating Src/Akt signaling. Chrysotoxine reduces cell viability and increases apoptosis level in H460 and H23 cells instead of non-tumor cell lines. Chrysotoxine shows rapid excretion and low bioavailability in rats. Chrysotoxine is used in cancer research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.52%
- CAS. Nr.: 156951-82-5
- Formel: C18H22O5
- Molecular Weight:318.36
-
Speicherung:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Chrysotoxine
More
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCI-H23 | IC50 |
145.47 μM
Compound: 3
|
Anti-cancer activity against human NCI-H23 cells
Anti-cancer activity against human NCI-H23 cells
|
[PMID: 32711292] |
| NCI-H460 | IC50 |
127.34 μM
Compound: 3
|
Cytotoxicity against human NCI-H460 cells assessed as cell viability by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as cell viability by MTT assay
|
[PMID: 32711292] |
Chrysotoxine (50 nM, 24 h) reduces cell viability and increases apoptosis level in H460 and H23 cells[1].
Chrysotoxine (5-20 nM, 72 h) suppresses the CSC populations in H460 and H23 cells[1].
Chrysotoxine (0-20 nM, overnight) decreases the stemness of H460 and H23 cells by suppressing
the Src-Akt activating mechanism[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:460, H23 cells
-
Concentration:0-20 µM
-
Incubation Time:Overnight
-
Result:Significant decreased the p-Src and p-Akt expression in a dose-dependent manner instead of Src and Akt.
Significantly reduced the down-stream stem cell transcription factor Sox2 as the decline of p-Src in H460 and H23 cells.
-
Cell Line:460, H23 cells
-
Concentration:0, 1, 5, 10, 20 and 50 µM
-
Incubation Time:24 h
-
Result:Significantly reduced cell viability and increased H460 and H23 cells cell apoptosis at 50 µM with IC50s of 127.34 and 145.47 µM, respectively.
Showed no cytotoxic effect on non-tumor cell lines at all tested concentrations.
-
Cell Line:460, H23 cells
-
Concentration:5-20 µM
-
Incubation Time:72 h
-
Result:Decreased approximately 30, 60, 90 and 95% of the H460 CSC spheroid size at day 7 with treated 1, 5,10 and 20 µM Chrysotoxine, respectively.
Decreased approximately 40, 60, 80 and 92% of the H23 CSC spheroid size at day 7 with treated 1, 5,10 and 20 µM Chrysotoxine, respectively.
| Parameters | Intravenous | Oral |
| AUC0–t (μg h/L) | 1257.6 ± 570.7 | 172.8 ± 118.9 |
| AUC0–∞ (μg h/L) | 1270.1 ± 560.6 | 202.5 ± 123.8 |
| MRT0–t (μg h/L) | 0.467 ± 0.056 | 1.2 ± 0.46 | MRT0–∞ (μg h/L) | 0.59 ± 0.21 | 2.4 ± 1.8 |
| t1/2Z ( h) | 1.4 ± 0.76 | 1.7 ± 1.1 |
| Tmax ( h) | / | 0.098 ± 0.040 |
| CLZ /F (L/h/kg) | 22.9 ± 11.2 | 668.7 ± 396.9 |
| VZ /F (L/kg) | 55.3 ± 54.1 | 1443.2 ± 943.0 |
| Cmax (μg/L) | 4961.2 ± 3254.8 | 408.8 ± 160.5 |
| F (%) | / | 3.4 ± 2.4 |